The Role of Endothelial Superoxide Dismutase 2 in Modulating Sickle Pathology

Sickle cell disease (SCD) patients suffer from hemolysis in microcirculation. On the one hand, hemoglobin and heme released from sickled red blood cells catalyze reactive oxygen species (ROS) generation by Fenton chemistry. On the other hand, sickled red blood cells occlude capillaries, creating a hypoxic condition that exacerbates ROS production. As an essential antioxidant mechanism, superoxide dismutase 2 (SOD2) detoxifies superoxide by converting it to hydrogen peroxide (H 2O 2) in the mitochondria. In SCD patients, despite the elevated ROS production, we found that SOD2 expression is suppressed in the pulmonary endothelium (Figure 1A,B). Therefore, we hypothesize the depletion of endothelial SOD2 compromises endothelial function and exacerbates the progression of SCD. To examine the role of endothelial SOD2, we silenced SOD2 gene expression (SOD2 KD) with siRNA in primary human pulmonary microvascular endothelial cells (hPMVECs). Knocking down SOD2 in hPMVECs accelerated mitochondrial superoxide production and compromised mitochondrial potential. However, mitochondrial respiration, the activity of respiratory complexes, and the cellular ATP content were not affected by SOD2 KD. An important function of endothelial cells is to form a barrier and sequester cellular and molecular contents in the blood. SOD2 KD hPMVECs exhibited increased albumin leakage and decreased transendothelial resistance, indicating a disrupted endothelial barrier(Figure 1C). The defect in the endothelial barrier was rescued by adding 4 mM H 2O 2(Figure 1D), suggesting SOD2-derived H 2O 2 may serve as a critical signaling molecule. Moreover, cell migration or proliferation was inhibited in SOD2 KD hPMVECs, which was examined by a scratch assay. Since both cell migration and barrier maintenance require focal adhesion assembly, we next investigated the role of SOD2 in focal adhesion dynamics. In an attachment assay, SOD2 KD reduced cell attachment rate on uncoated plates, which was blunted by fibronectin precoating, indicating a fibronectin-dependent defect in cell adhesion(Figure 1E,F). Notably, although fibronectin protein expression in hPMVECs was not altered, SOD2 KD decreased the dimer/monomer ratio. Furthermore, confocal images showed that fibronectin was retained in SOD2 KD cells(Figure 1G), highlighting the importance of SOD2 in fibronectin assembly. In conclusion, we demonstrated for the first time that SOD2 expression is diminished in the pulmonary endothelium of SCD patients and that endothelial SOD2 is crucial for endothelial function by facilitating fibronectin assembly. The importance of SOD2 in endothelial function may prove therapeutic value in SCD patients, which requires further investigation. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

JMJD6 Dysfunction Due to Iron Deficiency in Preeclampsia Disrupts Fibronectin Homeostasis Resulting in Diminished Trophoblast Migration

The mechanisms contributing to excessive fibronectin in preeclampsia, a pregnancy-related disorder, remain unknown. Herein, we investigated the role of JMJD6, an O2- and Fe2+-dependent enzyme, in mediating placental fibronectin processing and function. MALDI-TOF identified fibronectin as a novel target of JMJD6-mediated lysyl hydroxylation, preceding fibronectin glycosylation, deposition, and degradation. In preeclamptic placentae, fibronectin accumulated primarily in lysosomes of the mesenchyme. Using primary placental mesenchymal cells (pMSCs), we found that fibronectin fibril formation and turnover were markedly impeded in preeclamptic pMSCs, partly due to impaired lysosomal degradation. JMJD6 knockdown in control pMSCs recapitulated the preeclamptic FN phenotype. Importantly, preeclamptic pMSCs had less total and labile Fe2+ and Hinokitiol treatment rescued fibronectin assembly and promoted lysosomal degradation. Time-lapse imaging demonstrated that defective ECM deposition by preeclamptic pMSCs impeded HTR-8/SVneo cell migration, which was rescued upon Hinokitiol exposure. Our findings reveal new Fe2+-dependent mechanisms controlling fibronectin homeostasis/function in the placenta that go awry in preeclampsia.

Pten regulates collagen fibrillogenesis by fibroblasts through SPARC

Collagen deposition contributes to both high mammographic density and breast cancer progression. Low stromal PTEN expression has been observed in as many as half of breast tumors and is associated with increases in collagen deposition, however the mechanism connecting PTEN loss to increased collagen deposition remains unclear. Here, we demonstrate that Pten knockout in fibroblasts using an Fsp-Cre;PtenloxP/loxP mouse model increases collagen fiber number and fiber size within the mammary gland. Pten knockout additionally upregulated Sparc transcription in fibroblasts and promoted collagen shuttling out of the cell. Interestingly, SPARC mRNA expression was observed to be significantly elevated in the tumor stroma as compared to the normal breast in several patient cohorts. While SPARC knockdown via shRNA did not affect collagen shuttling, it notably decreased assembly of exogenous collagen. In addition, SPARC knockdown decreased fibronectin assembly and alignment of the extracellular matrix in an in vitro fibroblast-derived matrix model. Overall, these data indicate upregulation of SPARC is a mechanism by which PTEN regulates collagen deposition in the mammary gland stroma.

Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain

As a non-antibody scaffold, monobodies based on the fibronectin type III (FN3) domain overcome antibody size and complexity while maintaining analogous binding loops. However, antibodies and their derivatives remain the gold standard for the design of new therapeutics. In response, clinical-stage therapeutic proteins based on the FN3 domain are beginning to use native fibronectin function as a point of differentiation. The small and simple structure of monomeric monobodies confers increased tissue distribution and reduced half-life, whilst the absence of disulphide bonds improves stability in cytosolic environments. Where multi-specificity is challenging with an antibody format that is prone to mis-pairing between chains, multiple FN3 domains in the fibronectin assembly already interact with a large number of molecules. As such, multiple monobodies engineered for interaction with therapeutic targets are being combined in a similar beads-on-a-string assembly which improves both efficacy and pharmacokinetics. Furthermore, full length fibronectin is able to fold into multiple conformations as part of its natural function and a greater understanding of how mechanical forces allow for the transition between states will lead to advanced applications that truly differentiate the FN3 domain as a therapeutic scaffold.

Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain

As a non-antibody scaffold, monobodies based on the fibronectin type III (FN3) domain overcome antibody size and complexity while maintaining analogous binding loops. However, antibodies and their derivatives remain the gold standard for design of new therapeutics. In response, clinical therapeutic proteins based on the FN3 domain are beginning to use native fibronectin function as a point of differentiation. The small and simple structure of monomeric monobodies confers increased tissue distribution and reduced half-life, whilst the absence of disulphide bonds improves stability in cytosolic environments. Where multi-specificity is challenging with an antibody format that is prone to mis-pairing of chains, FN3 domains in the fibronectin assembly already interact with a large number of molecules. As such, multiple monobodies engineered for interaction with therapeutic targets are being combined in a similar beads-on-a-string assembly which improves both efficacy and pharmacokinetics. Furthermore, full length fibronectin is able to fold into multiple conformations as part of its natural function and a greater understanding of how mechanical forces allow for the transition between states will lead to advanced applications that truly differentiate the FN3 domain as a therapeutic scaffold.

Material-Driven Fibronectin Assembly Rescues Matrix Defects due to Mutations in Collagen IV in Fibroblasts

Basement membranes (BMs) provide structural support to tissues and influence cell signaling. Mutations in COL4A1/COL4A2, a major BM component, cause eye, kidney and cerebrovascular disease, including stroke. Common variants in these genes are risk factors for intracerebral hemorrhage in the general population. However, the contribution of the matrix to the disease mechanism(s) and its effects on the biology of cells harboring a collagen IV mutation remain poorly understood. To shed light on this, we engineered controlled microenvironments using polymer biointerfaces coated with ECM proteins laminin or fibronectin (FN), to investigate the cellular phenotype of primary fibroblasts harboring a COL4A2+/G702D mutation. FN nanonetworks assembled on poly(ethyl acrylate) (PEA) induced increased deposition and assembly of collagen IV in COL4A2+/G702D cells, which was associated with reduced ER size and enhanced levels of protein chaperones such as BIP, suggesting increased protein folding capacity of cells. FN nanonetworks on PEA also partially rescued the reduced stiffness of the deposited matrix and cells, and enhanced cell adhesion through β1-mediated signaling and actin-myosin contractility, effectively rescuing some of the cellular phenotypes associated with COL4A1/4A2 mutations. Collectively, these results suggest that biomaterials are able to shape the matrix and cellular phenotype of the COL4A2+/G702D mutation in patient-derived cells.